GenoMethods uses a methods-first, evidence-first publishing process for biotechnology news, analysis, explainers, guides, reviews, rankings, interviews and methodology pages.
The process is intended to move a subject from initial relevance through evidence, context and editorial review without treating publication speed as a substitute for reliable sourcing.
Editorial Lifecycle
- Idea. A topic is considered based on biotechnology relevance, reader usefulness, scientific or clinical significance, timeliness, source availability and public interest. Not every announcement requires coverage, and relevance depends on whether GenoMethods can add meaningful context within its editorial scope.
- Research. The central question is identified and relevant evidence is gathered, with primary or authoritative sources preferred where reasonably possible. Research should distinguish the source making a claim from evidence that independently supports it.
- Draft. The article is structured around documented facts, evidence, context and material limitations. The draft should make clear what is known, what is interpretation and what remains uncertain.
- Editorial Review. The draft is reviewed for unsupported assumptions, sourcing, clarity and whether its headline accurately represents the article. Review should also identify places where wording implies more certainty than the evidence supports.
- Source Check. Material references, names, dates, figures and links are checked where appropriate. The goal is to verify the details that materially affect the reader's understanding.
- Sensitive Claim Check. Clinical outcomes, safety, regulatory status, legal issues and major financial claims receive additional caution because errors or overstatement in these areas may have greater consequences.
- Publish. A human editor determines whether the available evidence and context support publication. Publication does not imply that future evidence cannot materially change the story.
- Update. Material new evidence, regulatory decisions, company developments or corrected facts may lead to later updates when they meaningfully alter the information readers need.
Content Labels
Sponsored, Partner Content or Press Release labels should be used only if content of that type actually exists.
News vs Analysis
News primarily reports documented developments and should avoid presenting interpretation as if it were part of the source record.
Analysis may interpret scientific, clinical, competitive or commercial significance, but the reader should be able to distinguish that interpretation from established fact.
Commercial Separation
GenoMethods currently displays third-party advertising through Google AdSense. Commercial relationships do not determine independent editorial conclusions, corrections or review outcomes.
Paid visibility does not determine editorial ranking position.
AI and Editorial Tools
GenoMethods uses AI-assisted tools only to create, prepare or edit images and other visual materials. AI is not used for article writing, drafting, rewriting, summarization, research, fact-checking, source monitoring, translation, metadata, descriptions, tagging, categorization, biographies or other editorial text.
Human editors remain responsible for research, sourcing, verification and publication decisions.
Corrections
Verified factual errors are handled under: Corrections Policy
Minor grammar, spelling, formatting or broken-link changes may not receive a separate correction note because they do not materially alter the meaning of the article.
Reader Feedback
Editorial: editorial@genomethods.org
Corrections: corrections@genomethods.org
Related Pages
1 Broadway
Cambridge, MA 02142
United States